Venus Medtech

Venus Medtech (Hangzhou) Inc. was founded in 2009 to focus on the design, development and commercialization of transcatheter heart valve products. The Company is the leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018. According to Frost & Sullivan, the Company had a 79.3% market share in China by implantation volume of transcatheter aortic heart valve replacement ("TAVR") products in 2018. Its self-developed product, VenusA-Valve, is the first TAVR product approved by the National Medical Products Administration ("NMPA") and commercialized in China. As the pioneer in the transcatheter heart valve industry in China, the Company enjoys first mover advantages. The Company believes that its first mover advantages, together with its comprehensive product pipeline covering all four heart valves, robust intellectual property portfolio with 193 issued patents and 196 patent applications as of November 18, 2019, and visionary management team, will serve as high entry barriers and differentiate the Company from its peers.